

Molecular characteristics of *eae*-positive clinical Shiga toxin-producing *Escherichia coli* in Sweden

Ying Hua^{a,b,*}, Xiangning Bai^{c,d,*}, Ji Zhang^e, Cecilia Jernberg^f, Milan Chromek^g, Sverker Hansson^{h,i}, Anne Frykman^{h,i}, Xi Yang^d, Yanwen Xiong^d, Chengsong Wan^{a,*} and Andreas Matussek^{b,j,k,l,m,*}

^aDepartment of Microbiology, School of Public Health, Southern Medical University, Guangzhou, People's Republic of China; ^bDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; ^cDivision of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden; ^dState Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China; ^emEpiLab, School of Veterinary Science, Massey University, Palmerston North, New Zealand; ^fThe Public Health Agency of Sweden, Solna, Sweden; ^gDivision of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; ^hDepartment of Pediatrics, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden; ⁱDepartment of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ^jLaboratory Medicine, Jönköping Region County, Jönköping, Sweden; ^kDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; ^lDivision of Laboratory Medicine, Oslo University Hospital, Oslo, Norway; ^mDivision of Laboratory Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

ABSTRACT

Shiga toxin (Stx)-producing *Escherichia coli* (STEC) can cause a wide range of symptoms from asymptomatic carriage, mild diarrhea to bloody diarrhea (BD) and hemolytic uremic syndrome (HUS). Intimin, encoded by the *eae* gene, also plays a critical role in STEC pathogenesis. Herein, we investigated the prevalence and genetic diversity of *eae* among clinical STEC isolates from patients with diarrhea, BD, HUS as well as from asymptomatic STEC-positive individuals in Sweden with whole-genome sequencing. We found that 173 out of 239 (72.4%) of clinical STEC strains were *eae* positive. Six *eae* subtypes ($\epsilon 1$, $\gamma 1$, $\beta 3$, θ , ζ and ρ) were identified *eae* and its subtype $\gamma 1$ were significantly overrepresented in O157:H7 strains isolated from BD and HUS patients. $\epsilon 1$ was associated with O121:H19 and O103:H2 strains, and $\beta 3$ to O26:H11 strains. The combination of *eae* subtype $\gamma 1$ and *stx* subtype (*stx*₂ or *stx*₁+*stx*₂) is more likely to cause severe disease, suggesting the possibility of using *eae* genotypes in risk assessment of STEC infection. In summary, this study demonstrated a high prevalence of *eae* in clinical STEC strains and considerable genetic diversity of *eae* in STEC strains in Sweden from 1994 through 2018, and revealed association between *eae* subtypes and disease severity.

ARTICLE HISTORY Received 22 August 2020; Revised 13 October 2020; Accepted 8 November 2020

KEYWORDS Shiga toxin-producing *Escherichia coli*; intimin; *eae* gene; gene diversity; hemolytic uremic syndrome; clinical significance

Introduction

Shiga toxin (Stx)-producing *Escherichia coli* (STEC), is an enteric foodborne pathogen that can be asymptomatic or cause mild diarrhea, bloody diarrhea (BD) or even hemolytic uremic syndrome (HUS) in infected humans [1,2]. HUS is the leading cause of acute renal failure in children with high morbidity and mortality [3]. Serotype O157:H7, associated with HUS and severe clinical outcomes, is the most predominant and virulent serotype among more than 400 serotypes that have been identified [2,4]. Nevertheless, since the early

2010s, non-O157 pathogenic serogroups, such as O26, O103 and O104, have been widely reported from HUS patients [5–7]. Ruminants, especially cattle, are the most important reservoir of STEC [8]. Direct contact with animals and their environment, consumption of undercooked beef, unpasteurized milk, other animal-derived products, contaminated water and vegetables are the main sources of human infections [9].

Pathogenicity of STEC in human is largely dependent on Stx, which is considered as the most important virulence factor. Stx, which is encoded by *stx* genes

CONTACT Ying Hua ✉ ying.hua@ki.se Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou, People's Republic of China; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Xiangning Bai ✉ xiangning.bai@ki.se Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden; State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China; Chengsong Wan ✉ gzwcs@smu.edu.cn Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou, People's Republic of China; Andreas Matussek ✉ anmatu@ous-hf.no Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Laboratory Medicine, Jönköping Region County, Jönköping, Sweden; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway; Division of Laboratory Medicine, Institute of Clinical Medicine, University of Oslo, Norway

*These authors contributed equally to this work.

Supplemental data for this article can be accessed at <https://doi.org/10.1080/22221751.2020.1850182>

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

located on lambdoid prophages, has two types, Stx1 and Stx2, where Stx2 shows much stronger correlation with severe symptoms [10,11]. The duration of *stx* shedding is a main cause of secondary person-to-person (fecal-oral) transmission, the longer duration poses a high transmission risk [6]. Besides Stx, intimate adherence of STEC to the intestinal epithelium is also an important process in the STEC pathogenesis, it can cause attaching and effacing (A/E) lesions, which is a hallmark of STEC pathogenesis [12,13]. Intimin, encoded by the *eae* gene located in the locus of enterocyte effacement (LEE) pathogenicity island [14], plays a determinant role in the formation of A/E lesions by inducing the effacement of microvilli and forming of actin pedestals [15,16]. Also, intimin cooperates with its translocated intimin receptor-Tir, to trigger host signalling events and actin nucleation, thus inducing lesion formation [17]. Moreover, STEC injects a series of effector proteins into host cells through a type III secretion system (T3SS), which is encoded by LEE pathogenicity island, to play its pathogenic role [18].

The full length of the *eae* gene is about 2,800 base pairs (bp). *eae* has several subtypes, owing to its heterogeneous 3' regions, which encoded protein that has been identified to be the intimin cell-binding domain (Int280a) [19]. There are at least 19 groups of *eae* subtypes, i.e. α , β , γ , ϵ , ξ , z , η , θ , τ , ι , κ , λ , μ , ν , υ , ω , π , ρ and σ , that have been defined so far [20]. It has been suggested that intimin alleles are responsible for different host specificity and tissue tropism [21]. Roger *et al.* showed that *eae* subtype γ 1 appeared to be the most frequent among O157:H7 and O145:H28/H25/H⁻ strains [22,23]. A previous study has investigated the genetic diversity of intimin in atypical Enteropathogenic *Escherichia coli* (EPEC), where intimin β 1 was suggested to be the most frequent subtype among atypical EPEC strains from diarrheal patients [24]. However, the molecular characteristics of *eae*-positive STEC strains, especially clinical strains, have rarely been described. Moreover, the relationship between *eae* subtypes and clinical symptoms, as well as duration of *stx* shedding remains to be addressed.

The aim of this study is therefore to investigate the *eae* subtypes and polymorphisms among clinical STEC strains isolated from STEC-positive individuals present with varying symptoms in Sweden, and to assess the association of *eae* subtypes with disease severity.

Materials and Methods

Ethics statement

The study was approved by the regional ethics committees in Gothenburg (2015/335-15) and Stockholm (2020-02338), Sweden, respectively.

Strain collection and clinical information

A total of 239 STEC strains were isolated from STEC-infected individuals from 1994 through 2018 in Sweden. Clinical data of STEC patients were collected through reviewing medical records as well as routine praxis used for the STEC surveillance performed in Sweden. The duration of bacterial shedding was determined as the time period from the first *stx*-PCR-positive sample to the first negative sample, and clinical symptoms were classified into HUS, bloody diarrhea (BD) and non-bloody stool (NBS) [25].

Whole-genome sequencing, assembly and annotation

Bacterial DNA was extracted and whole genomes were sequenced by Illumina HiSeq X platform at SciLifeLab (Stockholm, Sweden) and Ion Torrent S5 XL platform (Thermo Fisher Scientific, Waltham, Massachusetts, US) at The Public Health Agency of Sweden as previously described [26]. The Illumina sequencing reads were *de novo* assembled with SKESA (version 2.3.0) [27]. The Ion Torrent sequencing reads were *de novo* assembled with SPAdes (version 3.12.0) in "careful mode" [28]. The genome assemblies were annotated with Prokka (version 1.14.6) [29]. The assemblies of all strains in this study were deposited in GenBank with accession numbers and metadata shown in Table S1.

Serotyping and *stx* subtyping

Serotype was determined by comparing assemblies to the SerotypeFinder database (DTU, Denmark) (<http://www.genomicepidemiology.org/>) using BLAST+ v2.2.30 [30]. The *stx* subtypes were determined by ABRicae version 0.8.10 (<https://github.com/tseemann/abricate>). An in-house *stx* subtyping database was created with ABRicate by including representative nucleotide sequences of all identified *stx*₁ and *stx*₂ subtypes. The assemblies were then used to search against the *stx* subtyping database. Multilocus sequence typing (MLST) was conducted *in silico* using the on-line tool provided by the Warwick *E. coli* MLST scheme website (https://enterbase.warwick.ac.uk/species/ecoli/allele_st_search). Sequence types (STs) were determined based on the seven housekeeping allelic genes (*adh*, *fumC*, *gyrB*, *icdF*, *mdh*, *purA*, and *recA*) profile.

Eae subtyping and polymorphism analysis

The complete sequences of the *eae* gene were extracted from the genome sequences according to the genome annotation, and then aligned with reference sequences of all described *eae* subtypes downloaded from

GeneBank. The genetic distances of *eae* subtypes were computed using the Maximum Composite Likelihood method by MEGA 7.0 software, and a Neighbor-Joining tree was generated with 1,000 bootstrap resamplings. As earlier described [20], a 95% nucleotide sequence identity cut-off value was used to characterize an innovative *eae* subtype. *eae* genotypes (GTs) based on *eae* sequence polymorphism was used to determine the diversity within each *eae* subtype.

Comparison of clinical *eae*-positive STEC strains with strains from other sources

To assess the relationship of *eae*-positive clinical STEC strains in this study and strains from other sources, the MLST allelic profiles of *eae*-positive strains isolated from animals, meat and humans reported in a recent survey [20] were used for comparison. A minimum spanning tree was generated with BioNumerics software version 7.6 (Applied Maths, Belgium).

Statistical analyses

Fisher's exact test was used to analyze the association between *eae* subtypes and bacterial features or clinical outcomes, the statistical significance was determined by Statistica12 (StatSoft, Inc. Tibco), *p*-value <0.05 was considered statistically significant.

Results

Prevalence of *eae* in clinical STEC strains

Among 239 clinical STEC strains, *eae* was present in 173 (72.4%) strains, including 56 HUS-associated strains, and 117 non-HUS strains (44 from patients with BD and 73 from individuals with NBS). All 65 O157:H7 strains and 108 (62.1%) non-O157 strains carried *eae* ($p < 0.0001$). *eae* was overrepresented in strains from children (73.08%, $p = 0.011$). The presence of *eae* was significantly associated with BD, HUS, and O157:H7 (Table 1). However, no association was observed between the presence of *eae* and the duration of bacterial shedding.

Diversity and subtype of *eae* in correlation with clinical outcomes

Six *eae* subtypes, namely epsilon1 ($\epsilon 1$), gamma1 ($\gamma 1$), beta3 ($\beta 3$), theta (θ), zeta3 ($\zeta 3$) and rho (ρ), were assigned in 173 *eae*-positive STEC strains. $\gamma 1$ was present in 39.3% of all strains, being the most predominant subtype, followed by $\epsilon 1$ (30.6%) and $\beta 3$ (24.9%). GTs were analyzed to determine the diversity within each *eae* subtype. Twenty-nine unique *eae* sequences were obtained, among which, $\epsilon 1$ subtype had ten GTs (GT1-GT10), followed by $\beta 3$ (GT1-

Table 1. Prevalence of *eae* gene in 239 STEC strains isolated from STEC-positive individuals.^a

<i>eae</i>	No. (%)		<i>p</i> -value	No. (%)		<i>p</i> -value	No. (%)		<i>p</i> -value	
	HUS (n=60)	Non-HUS (n=179)		BD (n=51)	NBS (n=128)		O157:H7 (n=65)	Non-O157 (n=174)		Adult (n=80)
Positive	56 (93.33)	117 (65.36)	<0.0001*	44 (86.27)	73 (57.03)	65 (100.00)	108 (62.07)	44 (55.00)	76 (73.08)	0.011*
Negative	4 (6.67)	62 (34.64)		7 (13.73)	55 (42.97)	0 (0.00)	66 (37.93)	36 (45.00)	28 (26.92)	

HUS: hemolytic uremic syndrome; BD: bloody diarrhea; NBS: non-bloody stool.

^aThe association was analyzed between *eae* gene and clinical symptoms (HUS and non-HUS; BD and NBS), serotypes (O157 and Non-O157), age groups (Adult: ≥ 10 years; Child: <10 years), duration of bacterial shedding (Long: >24 days; Short: ≤ 24 days), only differences showing statistical significance were shown.

* Statistically significant difference.

GT8), γ 1 (GT1-GT5), θ (GT1-GT4), ζ 3 (GT1) and ρ (GT1) (Figure 1). Isolates with the same *eae* subtype clustered together with the corresponding references (Figure 1). Notably, γ 1 was statistically overrepresented in strains from BD and HUS patients, while β 3 was related to non-HUS strains (Table 2). No association was found between *eae* subtypes and the duration of bacterial shedding or age of patients (Table S2).

Eae subtypes and genotypes correlated with serotypes

In total, 173 *eae*-positive strains were typed into seventeen O serogroups and nine H types, which were assigned into 17 serotypes, O157:H7 (n=65, 37.57%) was the most predominant serotype. O157:H7 strains harbored *eae*- γ 1 (60, 92.31%), ϵ 1 (4, 6.15%) and θ (1, 1.54%). γ 1 was found to be statistically associated with O157:H7, while ϵ 1 and β 3 were related to non-O157 serotypes (Table 2). Among non-O157 serotypes, we found that ϵ 1 was associated with O121:H19 and O103:H2 serotypes, β 3 was associated with O26:H11. The only two strains with *eae* subtype ζ 3 were assigned to serotypes O84:H2 and O98:H21. Only O180:H2 strain carried *eae* subtype ρ (Table S3). All O121:H19 strains carried *eae* with one exception. ϵ 1/GT7 was found to be linked to O121:H19 ($p < 0.0001$).

Association of eae and its subtypes with stx subtypes

Overall, six *stx* subtypes and combinations were identified in 173 *eae*-positive STEC strains, namely, *stx*_{1a}, *stx*_{2a}+*stx*_{2c}, *stx*_{2a}, *stx*_{2c}, *stx*_{1a}+*stx*_{2a}, and *stx*_{1a}+*stx*_{2c}, among which *stx*₂ (57.2%) was more prevalent than *stx*₁ (35.3%). We found that the presence of *stx*₁+*eae* was significantly more prevalent in non-HUS STEC strains compared with HUS associated STEC strains. Notably, the presence of *stx*₂+*eae* was significantly linked to HUS associated STEC strains, and *stx*₁+*stx*₂+*eae* was linked to BD-related strains (Table 3).

*stx*_{1a} was the most predominant *stx* subtype, with 35.3% of strains carrying this subtype. *stx*_{1a}+*stx*_{2c} only existed in strains carrying *eae*- γ 1. *eae*- ρ subtype was only found in strains harboring *stx*_{2a}. Notably, ϵ 1 was associated with *stx*_{2a}, γ 1 was related to *stx*_{2a}+*stx*_{2c}, and *stx*_{1a}+*stx*_{2c}, β 3 was linked to *stx*_{1a} (Table S4).

Comparison of clinical eae-positive STEC strains with strains from other sources

Twenty-two sequence types (STs) were found in the 173 *eae*-positive STEC isolates (Table S1). ST11 was the most common sequence type, all 61 O157:H7

strains belonged to ST11. A minimum spanning tree was generated using 22 STs from this study and 18 STs from other sources reported previously [20]. Interestingly, isolates from the same source showed tendency to cluster closely. For instance, isolates from humans, independent on patients with BD, HUS, or individuals with NBS, clustered closely, while isolates from animals and raw meat showed closer relatedness. Notably, when grouped with *eae* subtypes, the majority strains belonging to the most predominant *eae* subtype γ 1 were grouped closely with a few exceptions. Similarly, strains with the same other *eae* subtypes were more likely to cluster closely (Figure 2).

Discussion

STEC strains harboring *eae* are suggested to be more pathogenic with a higher risk of developing HUS [31]. Little is known regarding the features and polymorphism of *eae* gene in STEC strains derived from patients as well as their association with disease severity. Here, we performed molecular characterization of *eae*-positive STEC strains from patients with a variety of symptoms as well as asymptomatic carriers. We found that 72.4% of clinical STEC strains were *eae* positive, out of which 37.6% were O157 strains, and 62.4% were non-O157 strains. All clinical O157 strains were *eae* positive, while 62.1% of non-O157 strains carried *eae*, which is much higher than that of reported in a recent study where only 9.5% of non-O157 strains carried *eae* [20]. We found that 99.3% of HUS associated STEC strains possessed *eae*, which was significantly higher than *eae* prevalence in non-HUS STEC strains (65.4%). Additionally, *eae* positive rate in strains isolated from patients with BD (86.3%) was higher than that of individuals with NBS (57.0%). It's well-recognized that O157 is the primary cause of HUS [32–34]. We found that *eae* was significantly more prevalent in O157 strains, which may partially explain severe clinical outcomes of O157 strains.

The *eae* sequences in 173 STEC strains were classified into six subtypes, namely ϵ 1, γ 1, β 3, θ , ζ 3 and ρ . *eae*- γ 1 and ϵ 1 were the most common subtypes in this study. The prevalence of *eae* subtypes varies among studies. In a previous study, β 1 and ζ 3 were the most prevalent *eae* subtypes among STEC strains from different sources including diarrhea patients, raw beef and mutton, cattle, and yak [20]. *eae*- γ 1 and β 1 were reported to be the most widespread subtypes in STEC strains isolated from patients in Germany [35]. *eae* alleles examined in STEC strains isolated from ruminant animals also showed great genetic diversity. β and ζ were the most common *eae* subtypes in strains isolated from sheep, while β and θ were more prevalent in strains from cattle [36]. ϵ 1




Figure 1. Phylogenetic relationships of 29 different *eae* sequences identified in this study and 30 *eae* subtype reference sequences based on Neighbor-Joining method. The corresponding *eae* subtype (number of strains), strain name, serotype (number of strains), and *stx* subtype (number of strains) are shown. The *eae* subtypes/genotypes in this study are indicated in bold and different colors. Scale bar indicates genetic distance.

Table 2. Association between *eae* subtypes and clinical symptoms or bacterial variables.^a

<i>eae</i> subtype	No. strains	Symptoms						Serotypes											
		HUS (n=56)			Non-HUS (n=117)			BD (n=44)			NBS (n=73)			O157:H7 (n=65)			non-O157 (n=108)		
		pos	prevalence	p-value	pos	prevalence	p-value	pos	prevalence	p-value	pos	prevalence	p-value	pos	prevalence	p-value	pos	prevalence	p-value
ε1	53	14	25.00%	39	33.33%	0.27	13	29.55%	0.5	4	6.15%	49	45.37%	<0.001*					
γ1	68	33	58.93%	35	29.91%	<0.001*	19	43.18%	0.01*	60	92.31%	8	7.41%	<0.001*					
β3	43	5	8.93%	38	32.48%	<0.001*	11	25.00%	0.18	0	0.00%	43	39.81%	<0.001*					
θ	6	3	5.36%	3	2.56%	0.35	1	2.27%	0.88	1	1.54%	5	4.63%	0.28					
ζ3	2	1	1.79%	1	0.85%	0.59	0	0.00%	0.44	0	0.00%	2	1.85%	0.27					
ρ	1	0	0.00%	1	0.85%	0.49	0	0.00%	0.44	0	0.00%	1	0.93%	0.44					

HUS: hemolytic uremic syndrome; BD: bloody diarrhea; NBS: non-bloody stool; pos: number of positive strains.

^aThe association was analyzed between *eae* subtype and clinical symptoms (HUS and non-HUS; BD and NBS), age groups, serotypes, as well as duration of bacterial shedding, only variables with differences showing statistical significance were shown in this table.

* Statistically significant difference.

and γ1 were the most frequent *eae* subtypes among STEC strains isolated from healthy cattle [23]. The reason possibly lies in different sample sources and geographic distribution. It has been demonstrated that *eae* subtype β, ε, γ1, and θ are linked to more virulent strains [37]. Here, we found that γ1 was associated with severe clinical symptoms such as BD and HUS, highlighting the clinical significance of *eae* subtype γ1. However, the underlying mechanisms how different *eae* subtypes modulate the pathogenicity remains to be elucidated.

A diverse range of serotypes were observed among *eae*-positive STEC isolates. An earlier study showed association between serotypes and *eae* subtypes: O157 and O145 strains tended to harbor γ1, O103 and O121 harbored ε, O26 carried β, while O111 possessed θ and β [37]. In the present study, we observed a similar pattern. γ1 was significantly overrepresented in O157:H7 strains, also in line with a previous report of STEC strains derived from humans in Switzerland [22]. Similarly, ε1 was found to be prevalent in O121:H19 and O103:H2 strains. β3 was predominant in O26:H11 strains.

Notably, ε1 was found in four O157:H7 strains, which has been rarely reported before. In Germany, two O157:H16 strains isolated from diarrheal children carried *eae*-ε [38]. Another study reported O157:H16 strains isolated from water and meat also harbored *eae*-ε [39]. More data is needed to characterize the O157:H7 strains carrying *eae*-ε subtype.


The coexistence of *stx* and *eae*, especially *stx*₂, are more likely to enhance virulence and increase the severity of clinical outcomes in humans than those carrying *stx*₁ alone [40–42]. Consistently, we found that the presence of *stx*₂+*eae* in STEC strains is strongly associated with HUS. Interestingly, the presence of *stx*₁+*stx*₂+*eae* was linked to BD, while *stx*₁+*eae* was associated with NBS, supporting the evidence that the presence of *stx*₂, rather than *stx*₁, together with *eae* was associated with severe disease. Besides the finding that *eae* subtype γ1 was associated with HUS and O157:H7, γ1 was also found to be associated with *stx*_{2a}+*stx*_{2c} and *stx*_{1a}+*stx*_{2c}, these are high virulent *stx* subtypes, which could also contribute to the severity of clinical symptoms.

Longer duration of *stx* shedding poses higher risk for the transmission of STEC strains from person to person, STEC-infected patients below 15 years old are usually associated with longer shedding duration [6,43]. Consistently, we found that children had a longer shedding duration than adults (unpublished data). Several genes were reported to be associated with prolonged duration of shedding [25]. In this study, we found that the presence of *eae* was associated with children. However, the presence of *eae* and subtypes has no association with the duration of *stx* shedding. As the information of age and the duration of

Table 3. Association between presence of *stx* + *eae* and clinical symptoms.

<i>stx</i> + <i>eae</i>	No. (%)		<i>p</i> -value	No. (%)		<i>p</i> -value
	HUS (<i>n</i> = 56)	non-HUS (<i>n</i> = 117)		BD (<i>n</i> = 44)	NBS (<i>n</i> = 73)	
<i>stx</i> ₁ + <i>eae</i>	3 (5.36)	58 (49.57)	<0.0001*	14 (31.82)	44 (60.27)	0.003*
<i>stx</i> ₂ + <i>eae</i>	51 (91.07)	49 (41.88)	<0.0001*	23 (52.27)	26 (35.62)	0.08
<i>stx</i> ₁ + <i>stx</i> ₂ + <i>eae</i>	2 (3.57)	10 (8.55)	0.23	7 (15.91)	3 (4.11)	0.04*

* Statistically significant difference.

**Figure 2.** Minimum spanning tree of 22 STs from this study compared with 18 STs from other sources. Each circle represents a ST, with the pie divided proportionally to the number of isolates in that ST from different *eae* subtypes (A) or different sources (B).

shedding for some individuals is missing, further research is needed to understand the role of *eae* in children with longer duration of shedding.

In conclusion, here we describe the prevalence and genetic diversity of *eae* genes in clinical STEC isolates from Sweden from 1994 through 2018. Our results show that the majority of the clinical STEC isolates carry *eae* genes, which demonstrate highly genetic diversity. We found associations between *eae* subtypes and certain serotypes. Furthermore, *eae* subtype γ 1 is associated with strains causing severe symptoms. However, no correlation was observed between the presence of *eae* gene/subtypes and duration of bacterial shedding. Our study proposes that the coexistence of *eae* subtype γ 1 and *stx*₂ or *stx*₁+*stx*₂, could be used as a risk predictors for severe symptoms of STEC infections.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by the Scandinavian Society for Antimicrobial Chemotherapy Foundation [grant number SLS884041], National Natural Science Foundation of

China [grant number 81701977], and the Natural Science Foundations of Guangdong Province [grant number 2018B030311063 and 2019A1515111004]. All funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

ORCID

Cecilia Jernberg <http://orcid.org/0000-0002-1112-5306>

References

- [1] Kakoullis L, Papachristodoulou E, Chra P, et al. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. *J Infect.* 2019;79(2):75–94.
- [2] Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *The Lancet.* 2005;365(9464):1073–1086.
- [3] Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 infections [Journal article; Research Support, U.S. Gov't, P.H.S.]. *N Engl J Med.* 2000 2000-06-29;342(26):1930–1936.
- [4] Lynn RM, O'Brien SJ, Taylor CM, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. *Emerging Infect. Dis.* 2005 2005-01-01;11(4):590–596.
- [5] Delannoy S, Mariani-Kurkdjian P, Bonacorsi S, et al. Characteristics of Emerging human-pathogenic

- Escherichia coli* O26:H11 strains isolated in France between 2010 and 2013 and carrying the *stx2d* gene only. *J Clin Microbiol.* **2015**;53(2):486–492.
- [6] Vonberg RP, Höhle M, Aepfelbacher M, et al. Duration of fecal shedding of Shiga toxin-producing *Escherichia coli* O104:H4 in patients infected During the 2011 Outbreak in Germany: A Multicenter study. *Clin Infect Dis.* **2013** 2013-04-15;56(8):1132–1140.
- [7] Croxen MA, Law RJ, Scholz R, et al. Recent Advances in Understanding enteric pathogenic *Escherichia coli*. *Clin Microbiol Rev.* **2013** 2013-10-01;26(4):822–880.
- [8] Venegas-Vargas C, Henderson S, Khare A, et al. Factors associated with Shiga toxin-producing *Escherichia coli* shedding by Dairy and beef cattle [Journal article; research Support, Non-U.S. Gov't; research Support, N.I.H., Extramural; research Support, U.S. Gov't, Non-P.H.S.]. *Appl Environ Microbiol.* **2016** 2016-08-15;82(16):5049–5056.
- [9] Baschera M, Cernela N, Stevens MJA, et al. Shiga toxin-producing *Escherichia coli* (STEC) isolated from fecal samples of African dromedary camels. *One health.* **2019 Jun**;7, 100087:1-5.
- [10] Paton JC, Paton AW. Pathogenesis and Diagnosis of Shiga toxin-producing *Escherichia coli* infections. *Clin Microbiol Rev.* **1998** 1998-01-01;11(3):450–479.
- [11] Melton-Celsa AR. Shiga Toxin (Stx) Classification, Structure, and Function. *Microbiology Spectrum.* **2014**, 2014-08-22;2(4):1-13.
- [12] Girard F, Batisson I, Frankel GM, et al. Interaction of enteropathogenic and Shiga toxin-producing *Escherichia coli* and porcine intestinal mucosa: role of intimin and Tir in adherence [Journal article; research Support, Non-U.S. Gov't]. *Infect Immun.* **2005** 2005-09-01;73(9):6005–6016.
- [13] Lai Y, Rosenshine I, Leong JM, et al. Intimate host attachment: enteropathogenic and enterohaemorrhagic *Escherichia coli*. *Cellular Microbiology.* **2013**, 5 (11):1796–1808.
- [14] Oswald E, Schmidt H, Morabito S, et al. Typing of intimin genes in human and animal enterohemorrhagic and enteropathogenic *Escherichia coli*: characterization of a new intimin variant [Journal article; research Support, Non-U.S. Gov't]. *Infect Immun.* **2000** 2000-01-01;68(1):64–71.
- [15] Battle SE, Brady MJ, Vanaja SK, et al. Actin Pedestal formation by Enterohemorrhagic *Escherichia coli* Enhances bacterial host cell Attachment and Concomitant type III Translocation. *Infect Immun.* **2014**;82(9):3713–3722.
- [16] Shaw RK, Cleary J, Murphy MS, et al. Interaction of enteropathogenic *Escherichia coli* with human intestinal mucosa: role of effector proteins in brush border remodeling and formation of attaching and effacing lesions [Journal article; research Support, Non-U.S. Gov't]. *Infect Immun.* **2005** 2005-02-01;73(2):1243–1251.
- [17] Luo Y, Frey EA, Pfuetzner RA, et al. Crystal structure of enteropathogenic *Escherichia coli* intimin-receptor complex [Journal article; research Support, Non-U.S. Gov't]. *Nature.* **2000** 2000-06-29;405(6790):1073–1077.
- [18] Furniss RCD, Clements A. Regulation of the Locus of Enterocyte Effacement in Attaching and Effacing Pathogens. *Journal of Bacteriology.* **2018** 2017-07-31;200(2):e00336-17.
- [19] Kelly G, Prasannan S, Daniell S, et al. Structure of the cell-adhesion fragment of intimin from enteropathogenic *Escherichia coli* [Journal article; research Support, Non-U.S. Gov't]. *Nat Struct Biol.* **1999** 1999-04-01;6(4):313–318.
- [20] Yang X, Sun H, Fan R, et al. Genetic diversity of the intimin gene (*eae*) in non-O157 Shiga toxin-producing *Escherichia coli* strains in China. *Scientific Reports.* **2020**;10(1):3275–3283.
- [21] Zhang WL, Kohler B, Oswald E, et al. Genetic diversity of intimin genes of attaching and effacing *Escherichia coli* strains [Journal article; research Support, Non-U.S. Gov't]. *J Clin Microbiol.* **2002** 2002-12-01;40 (12):4486–4492.
- [22] Fierz L, Cernela N, Hauser E, et al. Characteristics of Shiga toxin-Producing *Escherichia coli* Strains Isolated during 2010–2014 from Human Infections in Switzerland. *Frontiers in Microbiology.* **2017**, 3 (8):1471–1477.
- [23] Blanco M, Schumacher S, Tasara T, et al. Serotypes, intimin variants and other virulence factors of *eae* positive *Escherichia coli* strains isolated from healthy cattle in Switzerland. Identification of a new intimin variant gene (*eae-eta2*). *BMC Microbiol.* **2005 May** 9;5:23.
- [24] Xu Y, Bai X, Zhao A, et al. Genetic diversity of intimin gene of atypical Enteropathogenic *Escherichia coli* isolated from human, animals and Raw Meats in China. *PLOS ONE.* **2016** 2016-03-31;11(3):e0152571.
- [25] Matussek A, Jernberg C, Einemo IM, et al. Genetic makeup of Shiga toxin-producing *Escherichia coli* in relation to clinical symptoms and duration of shedding: a microarray analysis of isolates from Swedish children. *Eur J Clin Microbiol Infect Dis.* **2017**;36 (8):1433–1441.
- [26] Lagerqvist N, Lof E, Enkirsch T, et al. Outbreak of gastroenteritis highlighting the diagnostic and epidemiological challenges of enteroinvasive *Escherichia coli*, County of Halland, Sweden, November 2017 [Journal Article]. *Euro Surveill.* **2020-03-01**;25(9): 1900466.
- [27] Souvorov A, Agarwala R, Lipman DJ. SKESA: strategic k-mer extension for scrupulous assemblies. *Genome Biology.* **2018**;19(1):153–165.
- [28] Bankevich A, Nurk S, Antipov D, et al. SPAdes: A New genome Assembly Algorithm and Its Applications to Single-cell sequencing. *J Comput Biol.* **2012**;19 (5):455–477.
- [29] Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics.* **2014** 2014-07-15;30(14):2068–2069.
- [30] Camacho C, Coulouris G, Avagyan V, et al. BLAST+: architecture and applications [Journal article; research Support, N.I.H., Extramural]. *BMC Bioinform.* **2009** 2009-12-15;10:421.
- [31] De Rauw K, Buyl R, Jacquinet S, et al. Risk determinants for the development of typical haemolytic uremic syndrome in Belgium and proposition of a new virulence typing algorithm for Shiga toxin-producing *Escherichia coli*. *Epidemiology and Infection.* **2019**;147:1-5.
- [32] Karmali MA. Factors in the emergence of serious human infections associated with highly pathogenic strains of shiga toxin-producing *Escherichia coli*. *Int J Med Microbiol.* **2018**;308(8):1067–1072.
- [33] Mora A, López C, Dhahi G, et al. Seropathotypes, Phylogroups, Stx subtypes, and intimin types of Wildlife-carried, Shiga toxin-producing *Escherichia coli* strains with the same characteristics as human-pathogenic isolates. *Appl Environ Microbiol.* **2012** 2012-04-15;78(8):2578–2585.

- [34] Preussel K, Hohle M, Stark K, et al. Shiga toxin-producing *Escherichia coli* O157 is more likely to lead to hospitalization and death than non-O157 serogroups—except O104 [Comparative study; Journal article]. *PLoS One*. 2013 2013-01-20;8(11):e78180.
- [35] Beutin L, Krause G, Zimmermann S, et al. Characterization of Shiga toxin-producing *Escherichia coli* strains isolated from human patients in Germany over a 3-year period [Journal article; Multicenter study; research Support. Non-U.S. Gov't]. *J Clin Microbiol*. 2004 2004-03-01;42(3):1099–1108.
- [36] Ramachandran V, Brett K, Hornitzky MA, et al. Distribution of intimin subtypes among *Escherichia coli* isolates from ruminant and human sources. *J Clin Microbiol*. 2003 Nov;41(11):5022–5032.
- [37] Tostes R, Goji N, Amoako K, et al. Subtyping *Escherichia coli* virulence genes isolated from Feces of beef cattle and clinical Cases in Alberta. *Foodborne Pathog Dis*. 2017;14(1):35–42.
- [38] Kozub-Witkowski E, Krause G, Frankel G, et al. Serotypes and virutypes of enteropathogenic and enterohaemorrhagic *Escherichia coli* strains from stool samples of children with diarrhoea in Germany. *J Appl Microbiol*. 2008 Feb;104(2):403–410.
- [39] Feng PC, Keys C, Lacher D, et al. Prevalence, characterization and clonal analysis of *Escherichia coli* O157: non-H7 serotypes that carry *eae* alleles. *FEMS Microbiol Lett*. 2010 Jul 1;308(1):62–67.
- [40] Brooks JT, Sowers EG, Wells JG, et al. Non-O157 Shiga toxin-producing *Escherichia coli* infections in the United States, 1983-2002 [Journal article]. *J Infect Dis*. 2005 2005-10-15;192(8):1422–1429.
- [41] Werber D, Fruth A, Buchholz U, et al. Strong association between Shiga toxin-producing *Escherichia coli* O157 and virulence genes *stx 2* and *eae* as Possible Explanation for Predominance of Serogroup O157 in patients with Haemolytic Uraemic syndrome. *Eur J Clin Microbiol Infect Dis*. 2003 2003-12-01;22(12):726–730.
- [42] Ethelberg S, Olsen KEP, Scheutz F, et al. Virulence Factors for hemolytic uremic syndrome, Denmark1. *Emerging Infect. Dis.*. 2004 2004-01-01;10(5):842–847.
- [43] Mody RK, Griffin PM. Editorial Commentary: fecal shedding of Shiga toxin-producing *Escherichia coli*: What should Be Done to Prevent secondary Cases? *Clin Infect Dis*. 2013 2013-04-15;56(8):1141–1144.